Quazinone

Last updated
Quazinone
Quazinone.svg
Clinical data
Other namesRo 13-6438
Routes of
administration 		Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (3R)-6-Chloro-3-methyl-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C11H10ClN3O
Molar mass 235.67 g·mol−1
3D model (JSmol)
  • Clc1cccc3c1CN2/C(=N\C(=O)[C@H]2C)N3

Quazinone (Dozonone) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease. [1] [2] [3] [4] [5] It acts as a selective PDE3 inhibitor. [6] [7] It is no longer available. [1]

Contents

See also

References

  1. 1 2 David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN   978-0-412-46630-4.
  2. ↑ Eigenmann R, Gerold M, Holck M (1984). "Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 511–9. doi: 10.1097/00005344-198405000-00021 . PMID   6202980. S2CID   35907876.
  3. ↑ Holck M, Thorens S, Muggli R, Eigenmann R (1984). "Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 520–30. doi: 10.1097/00005344-198405000-00022 . PMID   6202981. S2CID   13286049.
  4. ↑ Belz GG, Stern HC, Butzer R (1985). "Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers". Journal of Cardiovascular Pharmacology. 7 (1): 86–90. doi: 10.1097/00005344-198501000-00014 . PMID   2580156. S2CID   27819870.
  5. ↑ Daly PA, Chatterjee K, Viquerat CE, et al. (June 1985). "RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure". The American Journal of Cardiology. 55 (13 Pt 1): 1539–44. doi:10.1016/0002-9149(85)90969-5. PMID   4003296.
  6. ↑ Osinski MT, Schrör K (August 2000). "Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis". Biochemical Pharmacology. 60 (3): 381–7. doi:10.1016/S0006-2952(00)00328-2. PMID   10856433.
  7. ↑ Denis D, Riendeau D (February 1999). "Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". European Journal of Pharmacology. 367 (2–3): 343–50. doi:10.1016/S0014-2999(98)00987-X. PMID   10079010.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.